Business Finland grants Forendo Pharma a €3 million R&D loan for the development of a new drug for endometriosis treatment. The funding from Business Finland will enable Forendo to strengthen its women’s health portfolio, by progressing its early stage DUAL HSD Inhibitor program, targeting broader gynaecological conditions, including endometriosis, into preclinical development. The DUAL HSD Inhibitor compounds, currently in discovery phase, combine two mechanisms of actions whereby estrogen inhibition and direct anti-inflammatory effect can be combined locally in target tissues, without affecting systemic hormones.
Forendo Pharma’s lead program, HSD17B1 Inhibitor FOR-6219, is entering phase I studies during second quarter of 2018. The DUAL Inhibitor program was initiated in 2016 and Forendo is planning to select the product candidate for further development in 2019.
Please view the full text press release by clicking here: Pdf version of the press release